Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Hematopoietic Stem Cell Transplant For Patients With Dyskeratosis Congenita and Severe Aplastic Anemia.

Next Previous
Trial Profile

Hematopoietic Stem Cell Transplant For Patients With Dyskeratosis Congenita and Severe Aplastic Anemia.

Status: Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 18 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alemtuzumab; Antithymocyte globulin; Cyclophosphamide; Fludarabine; Methylprednisolone
  • Indications Graft-versus-host disease
  • Focus Therapeutic Use

Most Recent Events

  • 05 Dec 2017 Biomarkers information updated
  • 14 Mar 2012 Planned end date changed from 1 Mar 2013 to 1 Nov 2014 as reported by ClinicalTrials.gov.
  • 14 Jul 2009 Trial phase change from II to II/III as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top